Search
# Popular search #
0%
# Popular search #
Stock Code
603087.SHGan & Lee CEO Du Kai and Brazilian Health Minister Convene to Forge New Frontiers in Diabetes Prevention and Treatment
Gan & Lee Pharmaceuticals' Insulin Glargine Receives DRAP Approval in Pakistan
Gan & Lee Pharmaceuticals' Insulin Aspart 30 Receives NPRA Approval in Malaysia
Gan & Lee Pharmaceuticals Announced First Participant Dosed in a Phase 3 Clinical Study (OPTIMUM-1) of Bofanglutide (GZR18) Injection in Chinese Patients with Type 2 Diabetes Mellitus
Gan & Lee Pharmaceuticals Announced First Participant Dosed in a Phase 3 Clinical Study (SUPER-3) of Once-weekly Basal Insulin GZR4 Injection in Chinese Patients with Type 2 Diabetes Mellitus
Gan & Lee Pharmaceuticals Announced First Participant Dosed in a Phase 3 Clinical Study (SUPER-2) of Once-weekly Basal Insulin GZR4 injection in Chinese Patients with type 2 diabetes Mellitus
To be a world-class pharmaceutical company with focus on global business development
Registered in 20 countries
Products launched in 18 countries
Clinical trials conducted in 12 countries
Registered in 20 countries
Products launched in 18 countries
Clinical trials conducted in 12 countries
This website uses cookies to give users like yourself the best possible content and experience. For more information about your choices regarding cookies, please review our Privacy Policy .
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.
